Allen M Goorin

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial
    Allen M Goorin
    Dana Farber Cancer Institute, The Children s Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 20:426-33. 2002
  2. ncbi request reprint Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651
    Allen M Goorin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 21:1574-80. 2003
  3. ncbi request reprint Ovarian toxicity after chemotherapy: possible association with ifosfamide administration
    Mark R Palmert
    Division of Endocrinology, Department of Medicine, Children s Hospital, Boston, MA, USA
    Pediatr Blood Cancer 42:216-9. 2004
  4. ncbi request reprint Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:832-40. 2003
  5. ncbi request reprint Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2004-11. 2005
  6. doi request reprint Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group
    Paul A Meyers
    Children s Oncology Group, Arcadia, CA, USA
    J Clin Oncol 26:633-8. 2008

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial
    Allen M Goorin
    Dana Farber Cancer Institute, The Children s Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 20:426-33. 2002
    ....
  2. ncbi request reprint Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651
    Allen M Goorin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 21:1574-80. 2003
    ..The theoretic disadvantage is that it exposes a large tumor burden to marginally effective chemotherapy. The contribution of chemotherapy and surgery timing has not been tested rigorously...
  3. ncbi request reprint Ovarian toxicity after chemotherapy: possible association with ifosfamide administration
    Mark R Palmert
    Division of Endocrinology, Department of Medicine, Children s Hospital, Boston, MA, USA
    Pediatr Blood Cancer 42:216-9. 2004
  4. ncbi request reprint Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:832-40. 2003
    ..Recurrent osteosarcoma is a drug-resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET-743) as a salvage therapy in these patients...
  5. ncbi request reprint Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2004-11. 2005
    ....
  6. doi request reprint Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group
    Paul A Meyers
    Children s Oncology Group, Arcadia, CA, USA
    J Clin Oncol 26:633-8. 2008
    ..To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma...